Concert Pharma (CNCE) Tops Q4 EPS by 8c

Concert Pharma (NASDAQ: CNCE) reported Q4 EPS of $0.03, $0.08 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $10.3 million versus the consensus estimate of $11.24 million.

For earnings history and earnings-related data on Concert Pharma (CNCE) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• DA Davidson Reiterates Buy Rating on Boost Run (BRUN)
• Benchmark Reiterates Buy Rating on Odysight.AI Inc. (ODYS)